Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors

References

• Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med 1987;83:445–454.
   PubMed Web of Science ®Google Scholar
• Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997;96:111–116.
   PubMed Web of Science ®Google Scholar
• Spiers AS. Clinical manifestations of chronic granulocytic leukemia. Semin Oncol 1995;22:380–395.
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986;233:212–214.
   PubMed Web of Science ®Google Scholar
• Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 1995;15:5531–5541.
   PubMed Web of Science ®Google Scholar
• Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995;82:981–988.
   PubMed Web of Science ®Google Scholar
• Gordon MY. Biological consequences of the BCR/ABL fusion gene in humans and mice. J Clin Pathol 1999;52:719–722.
   PubMed Web of Science ®Google Scholar
• Van Etten RA. Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med 2007;204:461–465.
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as therapeutic agent for chronic myeloid leukemia. Blood 2005;108:2640–2649.
   Web of Science ®Google Scholar
• Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002;100:1965–1971.
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530–3539.
   PubMed Web of Science ®Google Scholar
• Hofmann WK, Jones LC, Lemp NA, et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002;99:1860–1862.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004;11:35–43.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, et al. Primitive quiescent Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319–325.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–141.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–2249.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401–412.
   PubMed Web of Science ®Google Scholar
• Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007;21:926–935.
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532–4539.
   PubMed Web of Science ®Google Scholar
• Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007;109:4016–4019.
   PubMed Web of Science ®Google Scholar
• Konig H, Holtz M, Modi H, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 2008;22:748–755.
   PubMed Web of Science ®Google Scholar
• Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008;111:2329–2338.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr/abl1-positive chronic myeloid leukemia. Blood 2009;113:1619–1630.
   PubMed Web of Science ®Google Scholar
• Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2010 Dec 13. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kroemer G, Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005;5:886–897.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007;8:931–937.
   PubMed Web of Science ®Google Scholar
• Baehrecke EH. Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol 2005;6:505–510.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol 2008;9:1004–1010.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726–734.
   PubMed Web of Science ®Google Scholar
• Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741–752.
   PubMed Web of Science ®Google Scholar
• Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005;120:237–248.
   PubMed Web of Science ®Google Scholar
• Maclean KH, Dorsey FC, Cleveland JL, Kastan MB. Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008;118:79–88.
   PubMed Web of Science ®Google Scholar
• Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 2005;6:439–448.
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007;117:326–336.
   PubMed Web of Science ®Google Scholar
• Degtyarev M, De Maziere A, Orr C, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 2008;183:101–116.
   PubMed Web of Science ®Google Scholar
• Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis inflammation and tumorigenesis. Cancer Cell 2006;10:51–64.
   PubMed Web of Science ®Google Scholar
• Paglin S, Hollister T, Delohery T, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 2001;61:439–444.
   PubMed Web of Science ®Google Scholar
• Ito H, Daido S, Kanzawa T, Kondo S, Kondo Y. Radiation-induced autophagy is associated with LC3 and its inhibition sensitizes malignant glioma cells. Int J Oncol 2005;26:1401–1410.
   PubMed Web of Science ®Google Scholar
• Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 2007;14:500–510.
   PubMed Web of Science ®Google Scholar
• Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004;11:448–457.
   PubMed Web of Science ®Google Scholar
• Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003;63:2103–2108.
   PubMed Web of Science ®Google Scholar
• Lu Z, Luo RZ, Lu Y, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 2008;118:3917–3929.
   Google Scholar
• Amaravadi RK Autophagy-induced tumor dormancy in ovarian cancer. J Clin Invest 2008;118:3837–3840.
   PubMed Web of Science ®Google Scholar
• Colell A, Ricci JE, Tait S, et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell 2007;129:983–997.
   PubMed Web of Science ®Google Scholar
• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010–4022.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Gajowniczek P, Way IP, et al. A common signaling cascade may underlie ‘addiction’ to the Src BCR-ABL and EGF receptor oncogenes. Cancer Cell 2006;10:425–435.
   PubMed Web of Science ®Google Scholar
• Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells including primary CML stem cells. J Clin Invest 2009;119:1109–1123.
   PubMed Web of Science ®Google Scholar
• Eisenberg-Lerner A, Bialik S, Kimchi A. Life and death partners: apoptosis autophagy and the cross-talk between them. Cell Death Differ 2009;16:966–975.
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471–484.
   PubMed Web of Science ®Google Scholar